XML 32 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2018
Revenue Recognition [Abstract]  
Revenue Recognition

12.

Revenue Recognition

Our source of product revenue for the year ended December 31, 2018, consists of sales of HEPLISAV-B in the U.S. The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the year ended December 31, 2018 (in thousands):

 

 

 

Chargebacks, discounts and other fees

 

 

Returns

 

 

Total

 

Balance at December 31, 2017

 

$

-

 

 

$

-

 

 

$

-

 

Provision related to current period sales

 

 

4,012

 

 

 

570

 

 

 

4,582

 

Credit or payments made during the period

 

 

(2,276

)

 

 

(1

)

 

 

(2,277

)

Balance at December 31, 2018

 

$

1,736

 

 

$

569

 

 

$

2,305

 

 

At December 31, 2018, reserves for chargebacks and discounts totaling $1.3 million were recorded as reductions of accounts receivable while the remaining reserves balances totaling $1.0 million were recorded as accrued liabilities in the condensed consolidated balance sheets.